Answers are grounded in this paper and cite their sources.
Background Dental caries, periodontitis, and peri-implantitis arise from an ecologically disturbed resident microbiome (dysbiosis) rather than a single pathogen, motivating dental materials and topical interventions that modulate rather than eradicate the oral microbiome. Their human evidence has not been formally appraised from a clinical perspective. Methods We searched PubMed/MEDLINE, Embase, Web of Science, and ClinicalTrials.gov on 17 August 2026, supplemented by WHO ICTRP (including ChiCTR) and grey literature. Of 2311 records (2083 after deduplication), 125 full texts were assessed and eight randomized trials were included. The primary synthesis was restricted to trials reporting community-level microbiome sequencing (16S rRNA, metagenomic, or metatranscriptomic); culture/qPCR-only trials were reviewed as contextual narrative evidence. Risk of bias was appraised with Cochrane RoB 2.0, and evidence synthesized narratively following SWiM. Results The eight trials span orthodontic adhesives, silver diamine fluoride, fluoride varnish, zinc and pyrophosphate dentifrices, probiotic lozenges, and zinc-oxide nanocoated implants. Several were associated with shifts in community composition without consistent evidence of broad depletion, though the evidence is heterogeneous: some reported significant between-group differences in specific taxa, others only within-group or descriptive changes. Only one trial was at low risk of bias, and it measured a surrogate microbial outcome. Some trials also measured clinical endpoints—silver diamine fluoride arrested caries and adjunctive probiotics improved periodontal parameters—but none was designed to demonstrate that a microbiome change mediated or predicted clinical benefit. Conclusions The eight trials are predominantly small, short, and with some concerns of bias, establishing shifts in community composition rather than demonstrated clinical benefit: although some interventions were accompanied by clinical improvements, none demonstrated that a microbiome change mediated or predicted the clinical outcome. The evidence is therefore insufficient to support a microbiome-modulating indication for the interventions reviewed, and should not be generalized across product categories (probiotic lozenges and dentifrices versus restorative biomaterials). The bottleneck to translation lies less in materials invention than in unresolved evidence, standardization, biosafety, and regulatory requirements.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: